Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors

NCT00849550 is registered in ClinicalTrials.gov with Herbert Hurwitz as lead sponsor.

NCT NCT00849550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00849550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors
Lead sponsor
Herbert Hurwitz
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2009
Completion date
December 31, 2012
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, unspecified adult solid tumor, protocol specific